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Type 2 diabetes mellitus (T2DM) is a global epidemic with an 
estimated worldwide prevalence of 415 million people in 
2015, which is projected to rise to 642 million people 
by 2040 (REF. 1). The very considerable health, social and 
economic burdens caused by T2DM1–3 present a major 
challenge to health-care systems around the world.
T2DM is a complex endocrine and metabolic disorder 
in which the interaction between genetic and environ-
mental factors generates a heterogeneous and progressive 
pathology with varying degrees of insulin resistance and 
dysfunction of pancreatic β cells and α cells, as well as 
other endocrine disturbances4–14 (FIG. 1). Insulin resist-
ance results from deficits in signalling pathways at the 
level of the insulin receptor and downstream, and T2DM 
emerges when β cells can no longer secrete sufficient 
insulin to overcome insulin resistance4,15–17. Overweight 
and obesity are major risk factors for the development of 
insulin resistance4,5,16,18–20.
Hyperglycaemia is the fundamental biochemical fea-
ture of T2DM, causing oxidative and nitrosative stress 
and activation of inflammatory pathways and endothelial 
dysfunction, as well as precipitating microvascular com-
plications and contributing to macrovascular disease, 
which are major causes of morbidity and mortality21. The 
results of several randomized controlled trials (RCTs) 
have demonstrated the short-term and long-term bene-
fits of improving glycaemic control in delaying the onset 
and reducing the severity of diabetes-related outcomes, 
particularly retinopathy, nephropathy, neuropathy and 
cardiovascular disease, and also mortality22–25. Attaining 
normal (or nearly normal) levels of blood glucose (where 
practical) is a major aim of T2DM treatment. Several 
strategies are available for this purpose: lifestyle changes, 
including dietary prudence, weight loss and physical 
activity, remain the cornerstones of management, but 
because of the progressive nature of T2DM and the dif-
ficulty in maintaining lifestyle changes in the long term, 
most patients also require oral therapies and (eventually) 
injectable treatments26.
For more than four decades, only two classes of oral 
glucose-lowering medications were available (biguanides 
and sulfonylureas), but in the past 20 years many more 
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treatment options have been introduced26,27 (TABLE 1). 
In this Review, we provide an evaluation of the thera-
pies available for the management of hyperglycaemia in 
patients with T2DM.
Glycaemic control and targets in T2DM
The treatment needs of patients with T2DM, and the 
responses to treatments, are highly variable, reflecting the 
complexity and variability of the pathogenic process28,29, 
so decisions must be made for each patient regarding the 
choice of therapy and glycaemic targets. Factors for con-
sideration include patient age, weight, duration of T2DM, 
risk of hypoglycaemia, cardiovascular risk, concomitant 
treatments, presence of complications and concomitant 
life-limiting illness. Other aspects, which are more diffi-
cult to quantify in clinical practice, include the reserve 
capacity for insulin secretion, genetic factors that might 
affect responses to therapies, the risk of developing future 
complications and the rate of disease progression30.
The long-term benefits of intensive glycaemic control 
on T2DM-related complications and mortality are well 
known, particularly when initiated promptly after diag-
nosis in young patients who do not yet have comorbid 
complications22–25. However, intensive glycaemic control 
is not without risks, such as hypoglycaemia, weight gain 
and possible cardiovascular events and mortality in high-
risk individuals. These risks might relate, at least in part, 
to the choice of glycaemic target and medications22,31–36, 
so an individualized management strategy is prefera-
ble36. The difficulty lies in the identification of patients in 
whom the risks associated with intensive glycaemic con-
trol outweigh the benefits. Stringent glycaemic control is 
not advised in elderly patients or in those with advanced 
disease, long T2DM duration or established cardiovascu-
lar disease27,36. An HbA1c target of 7% is commonly given 
in guidelines, but a lower target might be appropriate for 
newly diagnosed, young patients with T2DM and no 
complications, and a higher target might be more real-
istic for an elderly or frail patient with a long duration of 
disease and established complications.
Biguanides
The only biguanide available in clinical practice is met-
formin (dimethylbiguanide)37. Other biguanides (phen-
formin and buformin) have been withdrawn because of 
risks of lactic acidosis38. Biguanides were derived from 
the guanidine-rich herb Galega officinalis (French lilac), 
which was used in traditional medicine in Europe37,39. 
Metformin was introduced into clinical practice in 
Europe in 1957 and in the USA in 1995, and has become 
the most prescribed agent for T2DM worldwide37,39.
Mechanism of action
Metformin enters cells mainly via solute carrier 
family 22 member 1 (also known as organic cation 
transporter 1 (hOCT1)) and exerts multiple insulin- 
dependent and insulin-independent actions according 
to the level of drug exposure and the control of nutri-
ent metabolism within different tissues28,37,40–42 (FIG. 2). 
During treatment, the gut is exposed to high concen-
trations of metformin42, which interrupt the mito-
chondrial respiratory chain at complex I, and increase 
glucose utilization, anaerobic glycolysis and lactate 
production; some of the lactate can be converted back 
to glucose in the liver43. Lactate–glucose turn over 
causes energy dissipation, which might contribute to 
the weight neutrality (lack of weight gain or weight 
loss) observed in metformin-treated patients28,42. In the 
liver, metformin increases insulin signalling, reduces 
glucagon action and reduces gluconeogenesis and 
glyco genolysis28. Metformin can inhibit the mitochon-
drial redox shuttle enzyme glycerol-3-phosphate dehy-
drogenase, altering the hepatocellular redox state and 
resulting in reductions in the ATP:AMP ratio, hepatic 
gluconeogenesis and the conversion of lactate and 
glycerol to glucose, and activation of AMP-activated 
protein kinase (AMPK)44. In addition, metformin treat-
ment results in a shift toward the utilization of glucose 
relative to fatty acids as a cellular source of energy in 
the liver37. In muscle, metformin promotes insulin- 
mediated glucose uptake via solute carrier family 2, 
facilitated glucose transporter member 4 (GLUT-4)28.
As delayed-release formulations of metformin have 
achieved similar efficacies at lower doses compared with 
‘regular’ formulations, it seems that the gut is a major site 
of metformin action at therapeutic doses45. Metformin 
can increase circulating levels of glucagon-like peptide-1 
(GLP-1) from pretreatment levels, even in the absence 
of an oral glucose load and in individuals with and 
without T2DM46–50, by mechanisms that could include 
inhibition of sodium-dependent bile-acid transporters, 
which increase the availability of ileal bile acids to acti-
vate G-protein coupled bile acid receptor 1 (commonly 
known as TGR5) on enteroendocrine L cells. Compared 
with placebo, metformin reduces the activity of dipepti-
dyl peptidase 4 (DPP-4)46. Relative to pretreatment lev-
els, metformin increases GLP-1 secretion in response 
to an oral glucose load, via muscarinic (M3) and gas-
trin-releasing peptide receptor (GRP-R)-dependent 
pathways47–51. In mice, metformin stimulates expres-
sion of GLP-1 receptor (Glp-1r) on pancreatic β cells, 
mediated by peroxisome proliferator-activated receptor 
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(PPAR) α49. The effect of metformin on GLP-1 might 
contribute to its weight-neutral effect and to reduction 
in hepatic glucose output by inhibiting glucagon secre-
tion46–48. Metformin also affects the circadian control of 
glucose metabolism in liver and muscle42. Metformin-
induced AMPK activation results in phosphorylation 
of casein kinase I, which leads to degradation of the 
circadian clock component mPer2, thereby increasing 
expression of the CLOCK and BMAL1 circadian genes 
and causing phase advance in the circadian rhythm in 
treated rodents, compared with untreated controls52,53. 
The results of a study involving mice showed that met-
formin causes phase advance in the liver, but phase delay 
in muscle53, and the effects of metformin on circadian 
rhythm are blocked in mice with knock-out of Prkaa2, 
the gene encoding AMPK subunit α2 (REF. 52).
Pharmacokinetics
Metformin has an oral bioavailability of 40–60% and a 
plasma half-life of 4–9 h, and is eliminated unchanged 
in the urine mostly via tubular secretion rather than 
glomerular filtration28,54.
Pharmacodynamics
Metformin is widely used as a first-line pharmacotherapy 
in patients with T2DM, because of its efficacy, long-term 
safety record, low risk of hypoglycaemia, weight neutral-
ity and favourable effect on vascular disease36. Metformin 
treatment typically leads to a reduction in fasting plasma 
glucose (FPG) by 2–4 mmol/l and HbA1c by 1–2%, largely 
independent of age, weight and T2DM duration as long as 
some residual β-cell function remains28,39. In the 10-year 
follow-up data from the UK Prospective Diabetes Study 
(UKPDS), patients who received metformin had signifi-
cant risk reductions for any diabetes-related end point of 
21% (P = 0.01), diabetes-related death of 30% (P = 0.01) 
and myocardial infarction of 33% (P = 0.005) compared 
with overweight patients in the conventional therapy 
group23,28,55. Metformin might also be associated with a 
reduction in the risk of cancer in patients with T2DM, 
particularly prostate, pancreas and breast cancer28,42.
The progressive nature of T2DM can require the addi-
tion of other glucose-lowering treatments (including insu-
lin) to metformin15,36,56. Many fixed-dose combinations of 
drugs that include metformin are, therefore, available.
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Safety and adverse effects
The main adverse effects of metformin treatment are 
abdominal discomfort and other gastrointestinal effects, 
including diarrhoea37. Symptoms can diminish if the dose 
is reduced, but around 10% of patients cannot tolerate the 
drug at any dose37, possibly because of variants of hOCT1 
that lead to an increased concentration of metformin 
in the intestine57. The risk of metformin intolerance 
(defined as patients who stop metformin within the first 
6 months of treatment) is increased by concomitant use 
of drugs that inhibit hOCT1 activity (including tricyclic 
anti depressants, citalopram, proton-pump inhibitors, 
verapamil, diltiazem, doxazosin, spironolactone, clopi-
dogrel, rosiglitazone, quinine, tramadol and codeine; 
OR 1.63, 95% CI 1.22–2.17, P = 0.001) or the presence of 
two alleles of SLC22A1 associated with reduced function 
of hOCT1 rather than one allele or no deficient allele 
(OR 2.41, 95% CI 1.48–3.93, P <0.001)57.
Metformin is contraindicated in patients with advanced 
chronic kidney disease (CKD), notable liver disease or con-
ditions that might predispose to hypoxia or reduced tissue 
perfusion. However, observational and database studies 
indicate that advantage can be taken of the broad thera-
peutic index with metformin38,58,59, and careful attention to 
dose has enabled its use even in patients with cardiovas-
cular disease (including mild-to-moderate heart failure38,60 
and chronic obstructive pulmonary disease61). Adjusting 
the dose and monitoring renal function to ensure adequate 
elimination are important considerations, and metformin 
therapy should be stopped if hypoxaemia occurs62,63.
Results of the UKPDS showed that, compared with 
sulfonylureas and insulin in patients with obesity and 
newly diagnosed T2DM, metformin use was associated 
with significantly reduced rates of myocardial infarction, 
stroke and all-cause mortality (by 39%, 41% and 36%, 
respectively)64,65. The 10-year follow-up of the UKPDS 
showed that the reductions in myocardial infarction 
and mortality persist23. Database analyses have consist-
ently provided corroborating evidence for this effect65. 
Increasing levels of use of statins and renal-protective 
medications make it difficult to assess the effect of met-
formin on cardiovascular disease65, although several RCTs 
are ongoing to assess this effect65.
Sulfonylureas
Sulfonylureas were developed as variants of sulfonamides 
after the latter were reported to cause hypoglycaemia37,66. 
Sulfonylureas are classified as first-generation (such as tol-
butamide and chlorpropamide) and second-generation 
(such as glibenclamide (glyburide), gliclazide, glipizide 
and glimepiride)37; the second-generation drugs have 
greater potency, enabling treatment with lower doses.
Mechanism of action
Sulfonylureas act directly on pancreatic β cells by binding 
to the cytosolic face of ATP-binding cassette sub-family C 
member 8 (also known as sulfonylurea receptor 1 (SUR1)), 
which is part of the Kir6.2 ATP-sensitive potassium chan-
nel37,67. Binding closes the Kir6.2 channel, preventing 
potassium efflux and depolarizing the plasma membrane. 
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This opens local voltage-dependent calcium channels, 
increasing the influx of calcium and activating calci-
um-dependent signalling proteins, leading to insulin 
exocytosis (FIG. 3). In vitro studies show that persistent 
exposure to sulfonylureas for several days can desensi-
tize β cells and reduce the insulin-secretory response. 
However, studies in patients with T2DM have shown 
that a 25% increase in 24-h insulin secretion with the 
sulfonylurea glibenclamide is maintained for 6–10 weeks, 
although efficacy usually declines after 6–12 months of 
sulfonylurea therapy during clinical trials68.
Pharmacokinetics
Sulfonylureas vary considerably in their pharmacoki-
netic properties37,68–70 (see Supplementary informa-
tion S1 (table)). They have high bioavailability and reach 
peak plasma concentrations within 1.5–4.0 h68. They 
are metabolized in the liver to varying extents to form a 
number of active and inactive metabolites that are elimi-
nated along with unchanged drug via the bile and urine; 
caution is needed when treating patients with hepatic 
and/or renal impairment37. Half-lives are <10 h for some 
sulfonylureas, but extend to >24 h for others. Therapeutic 
effects are exerted for much longer than is indicated by 
the half-life if active metabolites are formed (as they are 
with glimepiride, glibenclamide and chlorpropamide)68. 
In general, first-generation sulfonylureas should be 
avoided in patients with CKD stages 3 or 4 or those who 
are undergoing dialysis, in whom gliclazide and glip-
izide are suitable without extensive dose adjustment71–73. 
Glimepiride is an option for patients with CKD but not 
receiving dialysis, on the proviso of low-dose initiation 
and careful titration71,73.
More than 90% of sulfonylureas in the circulation 
are bound to plasma proteins, which can lead to inter-
actions with other protein-bound drugs such as salicy-
lates, sulfonamides and warfarin37,68. Some medications 
potentiate the glucose-lowering effects of sulfonylureas 
by inhibition of their hepatic metabolism (for exam-
ple, some antifungals and monoamine oxidase inhibi-
tors), displacing them from binding to plasma proteins 
(for example, coumarins, NSAIDs and sulfonamides), 
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inhibiting their excretion (for example, probenecid) or 
antagonizing their mechanism of action (for example, 
diazoxide and other KATP-channel openers)37. Drugs 
such as rifampicin that induce sulfonylurea metabolism 
inhibit glucose-lowering by sulfonylureas37.
Altered sulfonylurea formulations can enable rapid 
onset of action (as is the case with micronized gliben-
clamide) or prolonged activity (for example, ‘Glipizide 
Extended Release’ and ‘Gliclazide Modified Release’) 
while maintaining glucose-lowering efficacy37,74–76.
Pharmacodynamics
As monotherapy, sulfonylureas can lead to reductions in 
FPG by 2–4 mmol/l and HbA1c by 1–2%28,37,68,70. However, 
the failure rates of sulfonylureas as monotherapy are 
greater than those of metformin or rosiglitazone15. 
Sulfonylureas can be used as first-line treatment options 
in patients who are intolerant of metformin, and can be 
used in combination with most other glucose-lowering 
medications, except meglitinides, which have a similar 
mechanism of action28,37. The size and durability of the 
response to sulfonylureas is positively associated with 
the reserve of β-cell function37.
Safety and adverse effects
Hypoglycaemia and weight gain are the main adverse 
effects associated with sulfonylureas. Weight gain of 
1–4 kg that stabilizes after about 6 months is common 
following drug initiation28. Weight gain is probably 
related to the anabolic effect of the increased insulin 
levels and reduction of glycosuria27,28,56.
Hypoglycaemia has been reported in 20–40% of 
patients receiving sulfonylureas, and severe hypoglycae-
mia (requiring third-party assistance) occurs in 1–7% 
of patients28,37,77, depending on the population, the defi-
nition of hypoglycaemia and the type and pharmaco-
kinetics of the sulfonylurea74. In a study involving six UK 
secondary care centres, self-reported hypoglycaemia 
prevalence was 39% (95% CI 30–49%), similar to that in 
patients with T2DM treated with insulin for <2 years77. 
The prevalence of self-reported severe hypoglycaemia 
was 7% (95% CI 3–13%)77. Continuous glucose moni-
toring (CGM) showed that 22% (95% CI 15–31%) of 
patients had at least one episode of interstitial glucose 
<2.2 mmol/l, similar to patients with T2DM treated 
with insulin for <2 years77. These results confirmed that 
the use of long-acting sulfonylureas with active metab-
olites is especially associated with hypoglycaemia28,37, 
and that the elderly, those living alone and those with 
renal or liver impairment, as well as car drivers, require 
extreme caution during treatment with sulfonylureas, as 
do those prescribing these drugs28,37. Education and glu-
cose self-monitoring are essential in patients receiving 
sulfonylureas; the results of an RCT78 involving patients 
receiving Gliclazide Modified Release showed that 
self-monitoring of blood glucose reduced both the risk of 
symptomatic hypoglycaemia and the reduction in HbA1c, 
compared with no monitoring.
The cardiovascular safety of sulfonylureas is 
controversial. In the 1970s, the University Group 
Diabetes Program raised concerns regarding increased 
cardiovascular disease risk with tolbutamide79, and since 
then many database studies, mostly retrospective, have 
suggested that sulfonylureas (particularly glibenclamide) 
are associated with less benefit than metformin against 
cardiovascular disease in patients with T2DM65. However, 
the results of RCTs such as UKPDS, ADVANCE and 
ACCORD did not show an increase in cardiovascular 
mortality or morbidity in sulfonylurea-treated patients65. 
The ongoing CAROLINA study80 comparing linaglitpin 
with glimepiride in patients with T2DM might help to 
define the cardiovascular safety of these drugs.
Meglitinides
The two main meglitinides (or glinides) are nateglin-
ide and repaglinide. The class takes its name from the 
meglitinide moiety of glibenclamide, which exerts an 
insulin-releasing effect independently of the sulfonyl 
moiety26,28,81.
Mechanism of action
Meglitinides bind to the benzamido site of SUR1 on 
β cells. This site is separate from the sulfonyl-binding 
site, but meglitinide binding has a similar effect to sulfo-
nylurea binding on the Kir6.2 channels37 (FIG. 3). However, 
the relatively rapid onset and short duration of action of 
meglitinides suits their use as prandial glucose-lowering 
agents37.
Pharmacokinetics
Repaglinide is almost completely absorbed, with peak 
plasma concentrations after about 1 h. Repaglinide 
binds to proteins in the circulation, and is rapidly 
metabolized in the liver (mostly by cytochrome P450 
3A4 (CYP3A4)), producing inactive metabolites that are 
mostly excreted in the bile. A plasma half-life of around 
1 h37,82,83 makes it suitable for patients with poor renal 
function. Taken approximately 15 min before a meal, 
repaglinide produces a prompt insulin response that 
lasts 4–6 h37. Bioavailability is unaffected by the inges-
tion of food. Repaglinide concentrations are positively 
affected by co-treatment with drugs that inhibit CYP3A4 
(such as ketoconazole, antibacterial agents, steroids and 
cyclosporine), and negatively affected by drugs that 
induce CYP3A4 (such as rifampicin, carbamazepine 
and barbiturates)83,84.
Nateglinide has a slightly faster onset and shorter 
duration of action (3–5 h) than repaglinide, but is also 
protein-bound in the circulation and metabolized in the 
liver by CYP3A4, producing metabolites that are mostly 
excreted in the urine37,83.
Pharmacodynamics
Repaglinide (0.5–4.0 mg) or nateglinide (60–180 mg) 
taken before meals produces dose-dependent increases 
in insulin concentrations and reduces postprandial and 
fasting hyperglycaemia37. Meglitinides are well-suited 
to patients with irregular meal patterns, or to elderly 
patients at high risk of hypoglycaemia37.
Meglitinides are usually used in combination with 
metformin, a thiazolidinedione or insulin, although they 
can be used as monotherapy. The results of RCTs have 
shown that HbA1c reductions are similar to, or slightly less 
than, those observed with sulfonylurea treatment when 
meglitinides are used as monotherapy or as an add-on 
to metformin37,83. Repaglinide can be used effectively in 
conjunction with basal and biphasic insulins85,86. In an 
RCT86 with treatment for 12 months, nonobese patients 
with long-term T2DM (n = 102) were randomly assigned 
to receive either repaglinide or metformin, both in com-
bination with biphasic insulin aspart 30/70 (30% soluble 
insulin aspart and 70% intermediate-acting insulin 
aspart), which was titrated to achieve an HbA1c level of 
<6.5%. At the end of treatment, HbA1c reductions were 
similar in both treatment groups (baseline versus study-
end HbA1c 8.15 ± 1.32 versus 6.72 ± 0.66% with metformin 
and 8.07 ± 1.49% versus 6.90 ± 0.68% with repaglinide, 
P = 0.2 for between-groups difference)86.
In a head-to-head RCT87 in which 150 drug-naive 
patients were randomly assigned to receive either 
repaglinide (0.5 mg per meal, maximum dose 4 mg 
per meal) or nateglinide (60 mg per meal, maximum 
dose 120 mg per meal) for 16 weeks, HbA1c reductions 
from an average of 8.9% at baseline were greater with 
repaglinide than nateglinide (−1.57% versus −1.04%, 
P = 0.002). Reductions in FPG were also greater 
with repaglinide than nateglinide (−57 mg/dl versus 
−18 mg/dl, P <0.001)87.
Safety and adverse effects
Results of studies with repaglinide and nateglinide 
have shown variable rates of hypoglycaemia, and gen-
erally less weight gain than with sulfonylureas83,88–92. In 
a head-to-head RCT87, hypoglycaemia (blood glucose 
<50 mg/dl) was more commonly associated with treat-
ment with repaglinide than with nateglinide (7% versus 
0%). Weight gain was also slightly greater in the rep-
aglinide group (1.8 kg versus 0.7 kg)87. As co-treatments 
with biphasic insulin, repaglinide and metformin 
resulted in similar rates of hypoglycaemia, but weight 
gain was less with metformin (difference in mean body 
weight = −2.51 kg, 95% CI −4.07 kg to −0.95 kg)86.
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Meglitinides can bind to the sulfonylurea receptor 2 
splice variants SUR2A and SUR2B, which are expressed 
by cardiovascular tissues83,93. In the large NAVIGATOR 
RCT94, nateglinide did not alter cardiovascular outcomes 
in people with impaired glucose tolerance who either had, 
or were at high risk of, cardiovascular disease. No asso-
ciation has been demonstrated between repaglinide and 
either cardiovascular disease or cardiovascular risk65,83,95.
α-Glucosidase inhibitors (AGIs)
Acarbose was the first AGI to be introduced, in the 
early 1990s; subsequently, miglitol and voglibose were 
introduced in some countries. AGIs are widely used 
in Asian populations that have diets in which complex 
carbohydrates predominate37.
Mechanism of action
AGIs competitively inhibit α-glucosidase enzymes in 
the brush border of enterocytes lining the intestinal 
villi, preventing the enzymes from cleaving disaccha-
rides and oligosaccharides into monosaccharides37,96. 
This action delays carbohydrate digestion and defers 
absorption distally along the intestinal tract, reducing 
blood-glucose excursions and lowering prandial insu-
lin levels37. Compared with controls, AGI treatment can 
also increase postprandial GLP-1 secretion and reduce 
secretion of glucose-dependent insulinotropic polypep-
tide (GIP)97,98. The affinities of AGIs vary for different 
α-glucosidase enzymes, resulting in specific activity pro-
files (for example, acarbose has greater affinity for glyco-
amylase than for other glucosidases, whereas miglitol is 
a stronger inhibitor of sucrase)37.
Pharmacokinetics
Acarbose is degraded by amylases and bacteria in the 
small intestine; <2% of the unchanged drug is absorbed 
(along with some of the intestinal degradation products). 
Absorbed material is mostly eliminated in the urine 
within 24 h37. Miglitol is almost completely absorbed, 
and is eliminated unchanged in the urine37.
Pharmacodynamics
Typical HbA1c reductions with AGI treatment are ~0.5%, 
mostly through reductions in postprandial glycaemia; 
reductions depend upon the amount of complex carbo-
hydrate in the diet28. In a noninferiority RCT99 of Chinese 
patients (n = 784) with newly diagnosed T2DM and mean 
HbA1c of 7.5%, acarbose resulted in HbA1c reductions 
similar to those with metformin (−1.1%, within groups 
difference 0.01%, 95% CI −0.12% to 0.14%). However, 
the sulfonylurea tolbutamide resulted in greater HbA1c 
reductions compared with acarbose (−1.8% versus 
−1.1%; mean difference 0.6%, 95% CI 0.2–1.0%) in 
newly diagnosed drug-naive patients with T2DM (n = 96, 
mean baseline HbA1c ~8%)100. Tolbutamide had a greater 
effect on FPG than acarbose, whereas their effects on 
postprandial glucose were similar100.
Safety and adverse effects
Gastrointestinal adverse effects of AGIs (flatulence, 
abdominal discomfort and diarrhoea) are commonly 
encountered and can lead to treatment withdrawal. 
Hypoglycaemia is uncommon. AGIs do not cause 
weight gain, and they have no clinically significant drug 
interactions.
The results of the STOP–NIDDM RCT showed that 
acarbose reduces the risk of developing T2DM, delays 
the onset of hypertension and reduces macrovascular 
events by 49% compared with placebo, but the total 
number of events was too small (n = 47) to draw firm 
conclusions65,101,102. A large RCT103 assessing the impact 
of acarbose on cardiovascular outcomes is ongoing.
Thiazolidinediones
Drugs derived from thiazolidinedione include piogl-
itazone, rosiglitazone and troglitazone. Troglitazone 
was introduced in 1997 and withdrawn soon after 
because of hepatotoxicity28. Rosiglitazone and piogl-
itazone were introduced in 1999. Rosiglitazone was 
discontinued in Europe and its use was restricted in 
the USA in 2008 after reports of an association with 
cardiovascular risk; the FDA lifted the restrictions in 
2013. Pioglitazone was discontinued in 2011 in some 
European countries pending enquires into a possible 
risk of bladder cancer.
Mode of action
Thiazolidinediones are agonists of the peroxisome pro-
liferator-activated receptor gamma (PPAR-γ), a nuclear 
receptor that is highly expressed in adipose tissue, 
and to a lesser extent in muscle, liver, β cells, vascular 
endothelium and macrophages37,104. PPAR-γ activation 
alters gene expression, promoting adipogenesis, insulin 
sensitivity and tissue glucose uptake, reducing inflam-
mation and altering energy balance104,105 in a tissue- 
specific manner. PPAR-γ activation reduces hepatic 
gluconeogenesis, modifies the blood lipid profile and 
possibly improves β-cell viability104,105. Differentiation 
of pre-adipocytes into new small insulin-sensitive 
adipocytes by PPAR-γ activation reduces circulating 
levels of free fatty acids, which reduces ectopic 
lipid accumulation in skeletal muscle and liver and 
rebalances the Randle (glucose–fatty acid) cycle in 
favour of glucose utilization by restricting availabil-
ity of free fatty acids as an energy source for hepatic 
gluconeogenesis28.
Pharmacokinetics
Thiazolidinediones reach peak plasma levels within 
1–2 h37. In the circulation, thiazolidinediones are almost 
entirely bound to plasma proteins, but their concentra-
tions are not sufficient to interfere with other protein- 
bound drugs37. Pioglitazone is metabolized by 
cytochrome P450 2C8 (CYP2C8) and CYP3A4 to weakly 
active metabolites that are eliminated via bile, whereas 
rosiglitazone is metabolized by CYP2C9 and CYP2C8 
to inactive metabolites that are excreted via urine37,106. 
Rifampicin induces expression of CYP3A4, resulting in 
a reduction in levels of rosiglitazone and pioglitazone, 
whereas the lipid-lowering fibrate gemfibrozil inhibits 
CYP2C8, leading to accumulation of rosiglitazone and 
pioglitazone106.
Pharmacodynamics
Maximal doses of thiazolidinediones can reduce HbA1c 
by 0.7–1.6% when used as monotherapy or in combina-
tion with metformin, sulfonylureas or insulin104,107. In an 
RCT108, patients with T2DM receiving metformin (n = 630, 
mean age ~56 years, mean diabetes duration ~5.5 years, 
baseline mean HbA1c 8.5–8.7%) were randomly assigned 
to either pioglitazone or gliclazide as an add-on treat-
ment. After 2 years, the changes in HbA1c were similar 
in the two arms (−0.89% with pioglitazone and −0.77% 
with gliclazide, P = 0.2 for between-groups difference), 
whereas pioglitazone resulted in greater reductions 
in FPG (−1.8 mmol/l versus −1.1 mmol/l, P <0.001)108. In 
another RCT108, patients with T2DM receiving a sulfon-
ylurea (n = 639, mean age ~60 years, mean T2DM dura-
tion ~7 years, baseline mean HbA1c 8.8%) were randomly 
assigned to either pioglitazone or metformin as an add-on 
treatment. After 2 years, the changes in HbA1c were sim-
ilar in the two arms (−1.03% with pioglitazone versus 
−1.16% with gliclazide, P = 0.17 for between-groups dif-
ference); reductions in FPG (around ~2 mmol/l) were also 
similar in the two arms108. Onset of the glucose-lowering 
effect of thiazolidinediones is gradual, taking 2–3 months 
to reach maximum effect37. The ADOPT trial15, in which 
4,360 patients with T2DM (mean age 56–58 years, base-
line HbA1c 7.4%, mostly <2 years T2DM duration) were 
randomly assigned to glyburide, metformin or rosigli-
tazone, showed that rosiglitazone as monotherapy has a 
more prolonged effect on glycaemic control (measured 
by HbA1c and FPG) than metformin or glyburide over 
5 years. The glucose-lowering efficacy of thiazolidine-
diones is generally gradual in onset over several weeks, 
varies considerably between individuals, and no defi-
nite predictors are known to identify responders versus 
nonresponders29.
Safety and adverse effects
Thiazolidinediones do not affect the risk of hypoglycae-
mia when used as monotherapy or in combination with 
metformin. Oedema (often identified by rapid weight 
gain) has been reported in 4–6% of patients receiving 
thiazolidinediones104; the observed fluid retention is the 
result of renal sodium reabsorption mediated by increased 
expression of sodium channel proteins in collecting duct 
epithelium28. Thiazolidinediones are associated with 
weight gain of 2–3 kg for each 1% drop in HbA1c, whether 
used as monotherapy or in combination with metformin 
or insulin104. The weight gain is usually in subcutaneous 
adipose tissue, whereas visceral fat is either reduced or 
unaltered104,109. In the ADOPT trial15, the weight gain with 
rosiglitazone over 5 years was greater than with gliben-
clamide (glyburide; treatment difference 2.5 kg, 95% CI 
2.0–3.1 kg, P <0.001), whereas no difference was observed 
in waist circumference (treatment difference 0.77 cm, 
95% CI −0.21 cm to 1.76 cm, P = 0.12).
The results of RCTs and observational studies show 
that, compared with control groups, long-term treat-
ment with thiazolidinediones lowers bone density and 
doubles the risk of fractures in patients with T2DM, par-
ticularly in women110. In the ACCORD trial111, women 
who received a thiazolidinedione had double the risk 
of nonspinal fracture compared with those not using a 
thiazolidinedione; this risk was reduced after discontin-
uation of the thiazolidinedione. A meta-analysis of RCTs 
showed that, compared with metformin, sulfonylureas 
or placebo, thiazolidinediones reduce bone mineral den-
sity at the lumbar spine (difference −1.1%, 95% CI −1.6% 
to −0.7%, P <0.0001), total hip (−1.0%, 95% CI −1.4% to 
−0.6%, P <0.0001), forearm (−0.9%, 95% CI −1.6% 
to −0.3%, P = 0.007) and femoral neck (−0.7%, 95% CI 
−1.4% to 0.0%, P = 0.06), effects that were not reversed 
after 1 year of stopping treatment in some studies112.
The cardiovascular safety of thiazolidinediones was 
questioned in a controversial meta-analysis that showed 
increased adverse cardiovascular outcomes in patients 
treated with rosiglitazone compared with controls with-
out rosiglitazone, prompting withdrawal of rosiglitazone 
in Europe and restricted use in the USA65,113. However, 
when the FDA re-examined the data from the RECORD 
study, no significant effect on cardiovascular risk 
was found65,114.
Pioglitazone is a ligand for PPAR-α (as well as PPAR-γ), 
and through PPAR-α it mitigates cardiovascular risk by 
positive effects on plasma levels of HDL cholesterol, reduc-
tions in plasma triglycerides and small dense LDL choles-
terol particles, with the production of larger, more buoyant 
particles115. Thiazolidinediones can also have beneficial 
effects on blood pressure and endothelial function65, but 
compared with pioglitazone, rosiglitazone increases levels 
of plasma LDL cholesterol and triglycerides65.
In the PROACTIVE trial32, compared with placebo, 
pioglitazone was associated with a numerical but non-
significant reduction in the composite outcome of all-cause 
mortality, nonfatal myocardial infarction, stroke, acute 
coronary syndrome, endovascular or surgical intervention 
in the coronary or leg arteries and amputation above the 
ankle (HR 0.90, 95% CI 0.80–1.02, P = 0.095). However, 
pioglitazone significantly lowered the occurrence of the 
secondary end point, a composite of all-cause mortal-
ity, nonfatal myocardial infarction and stroke (HR 0.84, 
95% CI 0.72–0.98, P = 0.027)32. In addition, pioglitazone 
reduced the risks of subsequent myocardial infarction 
and recurrent stroke by 16% and 47%, respectively65,116,117. 
Nonetheless, the risk of heart failure was higher in 
the pioglitazone group than the placebo group in the 
PROACTIVE trial, although this risk was not associated 
with increased mortality65.
However, both rosiglitazone and pioglitazone can 
cause congestive heart failure in patients who already 
have diastolic dysfunction, because of the propensity 
for oedema65. The effects of rosiglitazone on coronary 
artery disease are not clear, but pioglitazone might be 
beneficial65,118–122.
DPP-4 inhibitors
The currently available DPP-4 inhibitors (sitagliptin, 
vildagliptin, saxagliptin, linagliptin and alogliptin)123 
are licensed as monotherapy, dual therapy, triple ther-
apy and in combination with insulin, but there are some 
minor variations in licensing between agents. In addi-
tion, once-weekly DPP-4 inhibitors (omarigliptin and 
trelagliptin) are licensed in Japan124,125.
Mechanism of action
The action of DPP-4 inhibitors causes elevation of cir-
culating levels of incretin hormones, notably GLP-1 
and GIP. The incretin effect is the ability of intestinal 
factors to enhance nutrient-induced insulin responses 
during feeding by 50–70% in healthy individuals126,127; 
this effect is much diminished in T2DM. GIP is secreted 
by K cells in the duodenum and jejunum in response to 
ingestion of carbohydrates and lipids128–130. In addition 
to its incretin effect, GIP reduces gastric acid secretion 
and has roles in adipogenesis and possibly β-cell prolif-
eration128,130–133. GLP-1 is secreted by L cells mainly in 
the distal ileum and colon128,130, and accounts for most 
of the incretin effect128,134, including insulin biosyn-
thesis135,136. Additionally, GLP-1 causes a reduction in 
glucagon secretion, and has extrapancreatic actions 
that enhance satiety and delay gastric emptying (see 
Supplementary information S2 (box))127,134,137–139.
GIP and GLP-1 are rapidly degraded by DPP-4 
(REF. 128), which acts on peptides to cleave N-terminal 
dipeptides with alanine (as in the incretins) or proline at 
position N2 (REF. 130). DPP-4 exists free in the circulation 
and also attached to endothelial cells130,140, and is widely 
expressed in human tissues, including the intestine and 
portal system130. GLP-1 and GIP are generally inacti-
vated almost immediately following secretion, and have 
half-lives of <2 min and 5–7 min, respectively128,130,141,142. 
Compared with placebo treatment, DPP-4 inhibition 
results in a 2–3-fold increase in postprandial active GLP-1 
levels143,144. Unlike GLP-1 receptor agonists (GLP-1RAs), 
which can have an effect equivalent to a >10-fold increase 
in GLP-1, DPP-4 inhibitors do not delay gastric emptying 
or increase satiety and weight loss, but they do avoid 
initial nausea and vomiting145,146.
Pharmacokinetics
Currently available DPP-4 inhibitors can produce 
77–99% inhibition of DPP-4 activity and are appropri-
ate for once-daily dosing, except for vildagliptin (twice-
daily), and omarigliptin and trelagliptin (once-weekly). 
They are predominantly excreted in the urine, except for 
linagliptin, which does not require dose adjustment in 
patients with CKD (see Supplementary information S3 
(table))123,147–151.
DPP-4 inhibitors have little or no interaction with 
other glucose-lowering agents or drugs commonly used in 
patients with T2DM123,152, possibly because DPP-4 inhib-
itors are neither inducers nor inhibitors of cytochrome 
P450 isoforms, and are not appreciably bound to plasma 
proteins152. However, saxagliptin is metabolized to an 
active metabolite by CYP3A4 and CYP3A5 (REFS 123,152).
Pharmacodynamics
On average, DPP-4 inhibitors reduce postprandial glucose 
excursions by ~3 mmol/l, and FPG by ~1.0–1.5 mmol/l28,123. 
A meta-analysis153 that assessed the efficacy of DPP-4 
inhibitors as monotherapy or as add-on therapy to 
other oral agents included placebo-controlled or active- 
controlled RCTs of DPP-4 inhibitors (n = 98 trials, 24,163 
patients) of 12–54 weeks duration, with ≥30 patients in 
each treatment arm. The mean ages of the participants 
in all but two of these studies were 50–62 years; 88 of the 
98 trials included were double-blinded and 10 were open- 
label design153. The results showed that DPP-4 inhibitors 
reduce HbA1c by −0.77% (95% CI −0.82% to −0.72%) 
from an average baseline of 8.05%153. In 18 RCTs with 
a duration of 52–54 weeks, DPP-4 inhibitors resulted in 
HbA1c reductions of −0.84% (95% CI −0.99% to −0.68%, 
P <0.0001), whereas in 26 RCTs of 12–18 weeks dura-
tion, the HbA1c reduction was −0.68% (95% CI −0.75% 
to −0.61%, P <0.0001)153.The HbA1c reductions were 
largely similar across the class, but results from direct 
head-to-head trials are limited. In this meta-analysis, the 
HbA1c reductions according to DPP-4 inhibitor were: 
vildagliptin 50 mg (n = 26, age 56.3 years, baseline HbA1c 
8.06%) −0.88% (95% CI −1.00% to −0.75%, P <0.0001); 
sitagliptin 100 mg (n = 37, age 55.2 years, baseline HbA1c 
8.05%) −0.79% (95% CI −0.87% to −0.71%, P <0.0001); 
saxagliptin 5 mg (n = 13, age 55.4 years, baseline HbA1c 
8.01%) −0.70% (95% CI −0.79% to −0.62%, P <0.0001); 
linagliptin 5 mg (n = 13, age 59.0 years, baseline HbA1c 
8.05%) −0.55% (95% CI −0.65% to −0.45%, P <0.0001); 
alogliptin 25 mg (n = 11, age 55.2 years, baseline HbA1c 
8.14%) −0.76% (95% CI −0.86% to −0.66%, P <0.0001)153. 
Reductions in HbA1c were greater in patients with base-
line HbA1c >9.0%, compared with HbA1c ≤9.0%153. For 
RCTs with basal HbA1c <7.5% (n = 8, age 57.4 years, 
baseline HbA1c 7.32%) the HbA1c reduction was 
−0.63% (95% CI −0.78% to −0.48%, P <0.0001); for 
basal HbA1c 7.5–8.0% (n = 28, age 57.6 years, baseline 
HbA1c 7.82%) the reduction was −0.70% (95% CI −0.76 
to −0.63, P <0.0001); for basal HbA1c 8.0–8.5% (n = 34, 
age 55.9 years, baseline HbA1c 8.15%) the reduction 
was −0.72% (95% CI −0.79% to −0.64%, P <0.0001); for 
basal HbA1c >9.0% (n = 30, age 54.2 years, baseline HbA1c 
8.63%) the reduction was −0.93% (95% CI −1.02% to 
−0.84%, P <0.0001)153.
A meta-analysis of 27 reports of 19 studies, including 
7,136 patients, showed that DPP-4 inhibitor monotherapy 
was associated with a smaller decline in HbA1c than met-
formin monotherapy (weighted mean difference (WMD) 
0.20%, 95% CI 0.08–0.32%, Poverall effect = 0.001). DPP-4 
inhibitors combined with metformin produced smaller 
declines than GLP-1RAs combined with metformin 
(WMD 0.49%, 95% CI 0.31–0.67%, Poverall effect <0.001) and 
sulfonylureas combined with metformin (WMD 0.07%, 
95% CI 0.03–0.11%, Poverall effect <0.001), but similar declines 
to pioglitazone combined with metformin (WMD 0.09%, 
95% CI −0.07% to 0.24%, Poverall effect = 0.28)154. In the 
studies comparing monotherapies, trial durations were 
24–206 weeks, and participants had mean T2DM dura-
tion of 1.0–4.4 years and mean HbA1c of 7.2–9.6%. In the 
trials of combination therapies, mean T2DM duration was 
5.0–7.3 years and mean HbA1c was 7.3–8.5%154.
The comparison of the efficacy of DPP-4 inhibi-
tors with sulfonylureas is complicated by multiple fac-
tors including study duration, renal function and the 
choice of sulfonylurea for the active comparator155. In 
a meta-analysis155 of 12 RCTs of ≥18 weeks duration 
that compared sulfonylureas head-to-head with DPP-4 
inhibitors, the mean changes from baseline in HbA1c were 
modestly but significantly smaller with DPP-4 inhibitors 
than with sulfonylureas (difference of mean changes in 
HbA1c 0.105, 95% CI 0.103–0.107, P <0.0001). However, 
several RCTs of 1–3 years duration showed similar HbA1c 
reductions for DPP-4 inhibitors and sulfonylureas150,155–164.
The glucose-lowering efficacy of DPP-4 inhibitors is 
greater in Asian patients with T2DM than in other ethnic 
groups (between-group HbA1c difference −0.26%, 95% CI 
−0.36% to−0.17%, P <0.001), and might be affected by 
genetic factors such as a TCF7L2 gene variant165,166. A 
meta-analysis of RCTs of ≥76 weeks duration suggested 
that the effect of DPP-4 inhibitors is not durable and 
lessens during the second year of treatment167.
Head-to-head comparisons of DPP-4 inhibitors
The number of head-to-head trials comparing DPP-4 
inhibitors is limited. The results of an RCT168 compar-
ing saxagliptin and sitagliptin as add-on treatment to 
metformin in 810 patients (age 58.4 years, diabetes 
duration 6.3 years, baseline HbA1c 7.7%) showed that 
HbA1c reductions over 18 weeks are similar with both 
treatments (adjusted mean changes in HbA1c −0.52 and 
−0.62%, respectively; between-group difference 0.09%, 
95% CI −0.01% to 0.20%). However, sitagliptin resulted 
in a slightly greater reduction in FPG (−0.60 mmol/l for 
saxagliptin versus −0.90 mmol/l for sitagliptin; treatment 
difference 0.30 mmol/l, 95% CI 0.08–0.53 mmol/l)168.
In another RCT169, 148 patients with T2DM and 
estimated glomerular filtration rate (eGFR) <30 ml/
min/1.73m2, who were either drug-naive or treated with 
any glucose-lowering agents were randomly allocated to 
vildagliptin 50 mg or sitagliptin 25 mg once daily. The 
treatments resulted in similar reductions in HbA1c over 
24 weeks (adjusted mean change in HbA1c −0.54% from a 
baseline of 7.52% with vildagliptin versus −0.56% from a 
baseline of 7.80% with sitagliptin, P = 0.874). Vildagliptin 
lowered FPG by 0.47 ± 0.37 mmol/l, whereas FPG 
increased in the sitagliptin group by 0.16 ± 0.43 mmol/l, 
but the difference between groups was not significant 
(P = 0.185)169.
In a phase III, noninferiority RCT170, 243 patients 
with T2DM that was inadequately controlled by diet 
and exercise were randomly assigned to receive trelaglip-
tin (100 mg once weekly), alogliptin (25 mg daily) or 
placebo for 24 weeks. Trelagliptin was noninferior to 
alogliptin and resulted in similar reductions in HbA1c 
(−0.33% versus −0.45%, respectively; least-squares mean 
difference (LSMD) 0.11%, 95% CI −0.054% to 0.281%). 
Both trelagliptin and alogliptin significantly reduced 
mean HbA1c compared with placebo (P <0.0001)170.
In another RCT171, 412 patients with T2DM, who 
were drug-naive or on oral glucose-lowering treatments, 
were randomly assigned to receive omarigliptin 25 mg 
weekly, sitagliptin 50 mg daily or placebo, for 24 weeks. 
At baseline, patients had mean HbA1c of 7.9%, 8.0% and 
8.1%, respectively, in the omarigliptin, sitagliptin and 
placebo groups171. Omarigliptin treatment resulted in 
HbA1c reduction of −0.66% (95% CI −0.76% to −0.57%), 
which was significantly greater than with placebo 
(P <0.001) and similar to sitagliptin (LSMD −0.02%, 
95% CI −0.15% to 0.12%), meeting the prespecified 
noninferiority criterion171.
Safety and adverse effects
DPP-4 inhibitors are generally well tolerated, and the 
incidence of adverse effects is similar to placebo and 
lower than other glucose-lowering agents154,172. The inci-
dence of gastrointestinal symptoms is lower with DPP-4 
inhibitors than with metformin or a GLP-1RA154. The 
risk of hypoglycaemia in patients treated with a DPP-4 
inhibitor is very low except when combined with 
sulfonylureas or insulin123,154,172.
DPP-4 has many substrates other than incretins, 
including bradykinin, encephalins, neuropeptide Y, 
peptide YY1–36, gastrin-releasing polypeptide, sub-
stance P, insulin-like growth factor 1, vasostatin 1, the 
α chains of thyrotropin, luteinizing hormone, chorionic 
gonado tropin and several chemokines, such as C-C motif 
chemokine 2 (monocyte chemotactic protein 1)173; how-
ever, no adverse effects relating to these substrates have 
been observed in clinical trials28,123,148. In addition, DPP-4 
is the T-cell activation antigen CD26, but no untoward 
immune-related effects have been demonstrated, either in 
Dpp4 knockout mice or with the use of DPP-4 inhibitors 
in animals or humans28.
Several meta-analyses and pooled analyses have 
shown that DPP-4 inhibitors (individually and as a 
class) are associated with reductions in cardiovascular 
events65,174. However, these studies were retrospective 
and not specifically designed to examine the effect of 
DPP-4 inhibitors on the incidence of cardiovascular 
disease65. The results of three RCTs (SAVOR–TIMI175,176, 
EXAMINE177 and TECOS178) demonstrated that saxa-
gliptin, alogliptin and sitagliptin are not associated with 
the risk of adverse cardiovascular outcomes65,175–178. The 
populations of patients in these trials were each slightly 
different. SAVOR–TIMI175,176 included patients with 
T2DM with either a history of, or a risk of, cardiovascu-
lar events. EXAMINE177 included patients with T2DM 
and an acute myocardial infarction or hospitalization for 
unstable angina in the preceding 15–90 days. TECOS178 
included patients with T2DM who were >50 years old 
and had established cardiovascular disease.
These studies were designed to look specifically at 
the effects of DPP-4 inhibitors on cardiovascular safety 
so that patients in the placebo arms received other glu-
cose-lowering therapies to minimize any differences in 
HbA1c between arms. In the SAVOR–TIMI study175,176, 
saxagliptin treatment was associated with a 3.5% inci-
dence of hospitalization for heart failure, compared with 
2.8% in the placebo arm (P = 0.007), with no increase in 
mortality, and this difference was independent of base-
line renal function, although compared with placebo, 
saxagliptin reduced the development and progression of 
microalbuminuria65,175,176. No effect on heart failure was 
observed in the EXAMINE177 or TECOS178 trials, and 
the mechanism underlying the effect that was seen with 
saxagliptin is unclear. An ongoing study (CAROLINA80) 
has been designed to examine the effect of linagliptin 
on cardiovascular outcomes with an active comparator 
(glimepiride) rather than placebo.
The individual results of the SAVOR–TIMI, EXAMINE 
and TECOS trials did not show any increased risk of pan-
creatitis or pancreatic cancer175–179, but a meta-analysis of 
these RCTs did demonstrate a significantly increased risk 
of acute pancreatitis in patients using DPP-4 inhibitors 
compared with those receiving standard care (OR 1.82, 
95% CI 1.17–2.82, P = 0.008)180.
GLP-1RAs
Exenatide (twice daily) was the first GLP-1RA, and 
was introduced in 2005. Two once daily GLP-1RAs 
(liraglutide and lixisenatide) and three once weekly 
GLP-1RAs (exenatide, albiglutide and dulaglutide) 
are also now available for combination therapy with 
oral glucose-lowering agents and basal insulin (except 
exenatide once weekly, which is not licensed to be used 
with basal insulin). Dulaglutide and albiglutide are also 
licensed as monotherapy in patients who are intolerant 
to metformin.
Exenatide (synthetic exendin-4), a peptide originally 
isolated from saliva of the lizard Heloderma suspectum 
(Gila monster)128,181, has 53% homology with human 
GLP-1 and contains an Ala8Gly substitution that con-
fers resistance to degradation by DPP-4 (REFS 128,182). 
Exenatide once weekly sustained-release formulation 
consists of exenatide embedded within biodegradable 
polymeric microspheres of poly(DL-lactic-co-glycolic 
acid)183. Liraglutide is a true analogue of GLP-1 with 
the addition of a 16-carbon fatty acid chain attaching 
Lys26 to albumin, to mask the DPP-4 cleavage site184. 
Albiglutide has two copies of GLP-1 in series, each with 
an Ala8Gly substitution, and this molecule is fused to 
albumin185. Lixisenatide is an exendin-4 analogue with 
six Lys residues added at the C terminus to confer resist-
ance to DPP-4 (REF. 186). Dulaglutide has two copies of a 
GLP-1 analogue (with amino acid substitutions Ala8Gly, 
Gly22Glu and Arg36Gly) covalently linked to an 
Fc fragment of human IgG4 (REF. 187).
Mechanism of action
GLP-1RAs mimic GLP-1 and activate the GLP-1 recep-
tor, potentiating nutrient-induced insulin secretion 
(FIG. 3), contributing to reductions in fasting glycaemia 
and postprandial glycaemia, and to weight loss188 (see 
Supplementary information S2,S4,S5 (box, table, table)). 
Therapeutic concentrations of GLP-1RAs are far higher 
than physiological levels of GLP-1, and although GLP-1 
deficiency has been described in patients with T2DM, this 
deficiency is not a universal characteristic of the disease188.
Pharmacokinetics
GLP-1RAs are delivered by subcutaneous injection. 
Exenatide is rapidly absorbed189. Tmax is ~2 h, half-life 
is 3–4 h189 and elimination is mostly renal by glomer-
ular filtration and proteolytic degradation190–192 (see 
Supplementary information S6 (table)). Relative to 
patients with normal renal function, exenatide clearance is 
decreased by 36% in patients with moderate renal disease 
(in whom it should be used with caution) and by 84% in 
those with severe renal disease (in whom it should not be 
used)193. The once weekly exenatide reaches therapeutic 
levels within 2 weeks and maximum concentrations by 
6 weeks194. The half-life of liraglutide is 10–15 h, with a 
Tmax of 9–12 h195–197. Lixisenatide has a half-life of 2–4 h 
and a Tmax of 1–2 h198, and exerts its main effect on the 
meal immediately after injection. Albiglutide has a Tmax 
of 3–5 days and a half-life of 6–7 days199. Dulaglutide 
has a Tmax of 12–72 h, a half-life of ~4 days and reaches 
steady-state levels by 2 weeks200 (see Supplementary infor-
mation S6 (table)). GLP-1RAs are not recommended in 
severe renal disease; they have limited drug interactions, 
but can affect the availability of other medicines, such 
as acetaminophen (paracetamol) and statins because of 
the delay in gastric emptying (except for exenatide once 
weekly, which has a minor effect on gastric emptying)27,201.
Pharmacodynamics
The efficacy of GLP-1RAs has been explored in large 
programmes of placebo-controlled and active-compar-
ator RCTs202–238 (see Supplementary information S4,S5 
(tables)).
Effect on glycaemic measures. Exenatide (twice daily) 
significantly reduces measures of glycaemic con-
trol when used as monotherapy or add-on therapy 
(see Supplementary information S4 (table))239–243. A 
meta-analysis244 of RCTs in which exenatide was an 
add-on to existing metformin therapy for 16–30 weeks 
showed that exenatide lowers HbA1c by 0.8% from an 
average baseline of 8.1 ± 0.6%. The effect of exenatide 
on HbA1c reduction was greater in patients with baseline 
HbA1c >9% than in those with HbA1c ≤9%239, and was 
maintained at 3 years240 and only deteriorated modestly 
through 6 years245,246.
Liraglutide improves glycaemic control when used 
as monotherapy or add-on therapy239,241,247,248 (see 
Supplementary information S4 (table)). Compared with 
glimepiride 8 mg daily, liraglutide 1.2–1.8 mg daily mon-
otherapy resulted in greater reductions in HbA1c from an 
average baseline of 8.3% (glimepiride −0.6%, liraglutide 
1.2 mg −0.9% and liraglutide 1.8 mg −1.1%; treatment 
difference for liraglutide 1.2 mg −0.31%, 95% CI −0.54% 
to −0.08%, P = 0.008; treatment difference for liraglutide 
1.8 mg −0.60%, 95% CI −0.83% to −0.38%, P <0.0001). 
A similar effect was seen for reductions in FPG (treat-
ment difference for liraglutide 1.2 mg −0.63 mmol/l, 
95% CI −1.17 mmol/l to −0.09 mmol/l, P = 0.02; treat-
ment difference for liraglutide 1.8 mg −0.99 mmol/l, 
95% CI −1.53 mmol/l to −0.45 mmol/l, P <0.001) and 
also postprandial glucose over 104 weeks247. In pooled 
patient data from seven phase III RCTs from the lira-
glutide development programme, with 26  weeks 
of liraglutide 1.8 mg, HbA1c reductions were less in 
patients with baseline HbA1c ≤7.5% than in those with 
HbA1c >9.0% (−0.7% versus −1.8%)249.
Lixisenatide significantly decreases HbA1c and post-
prandial glucose when used as monotherapy or add-on 
therapy210–215,250–257. In a meta-analysis of RCTs, com-
pared with placebo, lixisenatide treatment produced 
reductions in 2 h postprandial glucose from baseline 
(LSMD −4.9 mmol/l, P <0.001), glucose excursion 
(LSMD −4.5 mmol/l, P <0.001) and postprandial gluca-
gon (LSMD −19.0 ng/l, P <0.001)256. Compared with pla-
cebo, lixisenatide also reduced HbA1c and postprandial 
glucose, but not FPG, when added to basal insulin257.
Exenatide once weekly reduces HbA1c, FPG and post-
prandial glucose when used as monotherapy or add-on 
treatment218,239,241,258. Exenatide once weekly monotherapy 
has been noninferior to metformin, superior to sitagliptin 
and similar to pioglitazone with regard to HbA1c reduc-
tion in RCTs at 26 weeks239,258. Addition of exenatide once 
weekly to metformin is more effective for the achieve-
ment of glucose control than addition of either sitagliptin 
or pioglitazone to metformin218,239. In a study involving 
456 patients with T2DM treated with metformin alone 
or with a sulfonylurea, addition of exenatide once weekly 
resulted in similar HbA1c reductions to addition of insu-
lin glargine; the effect of exenatide once weekly persisted 
at 3 years222,236,239. Similarly, addition of exenatide once 
weekly to oral glucose-lowering medication resulted in 
greater HbA1c reductions over 26 weeks than addition 
of once daily or twice daily insulin detemir239,259. In the 
extension phase of the DURATION-1 trial260, patients 
received exenatide once weekly for up to 5 years, and 
improvements in HbA1c and FPG were maintained over 
this period. However, 40% of patients did not complete 
the study. Most of the loss of follow-up was because of 
withdrawal of consent, and only eight patients withdrew 
because of “loss of glucose control”. No differences were 
identified in baseline characteristics between those who 
completed and did not complete the study, and HbA1c 
reduction at 5 years was evident in the intention-to-treat 
analysis (−1.2% ± 0.1%) and the analysis of patients who 
completed the extension (−1.6% ± 0.1%).
Albiglutide has beneficial effects on glycaemic con-
trol when used as monotherapy or add-on therapy in 
phase III studies250,261,262. In an RCT lasting 104 weeks, 
treatments were added to metformin, and albiglutide 
provided significantly greater reductions in HbA1c and 
FPG than placebo, sitagliptin or glimepiride226. As an 
add-on to treatment with metformin and sulfonylurea, 
albiglutide did not meet the prespecified noninferior-
ity margin for the difference in the change of HbA1c of 
0.3% compared with pioglitazone over 52 weeks223. As 
an add-on to metformin (with or without sulfonylurea), 
albiglutide resulted in similar HbA1c reductions to insu-
lin glargine over 52 weeks224. As an add-on to insulin 
glargine, albiglutide was noninferior to insulin lispro at 
26 weeks, but did not meet the noninferiority margin 
at 52 weeks250,263.
Dulaglutide 0.75 mg and 1.5 mg weekly treatments 
were more effective than metformin and sitagliptin when 
used as monotherapy or as add-on therapy to other oral 
glucose-lowering treatments over 52 weeks232,234,250. In 
addition to metformin and sulfonylureas over 52 weeks, 
compared with daily insulin glargine, dulaglutide 1.5 mg 
weekly was more effective and dulaglutide 0.75 mg was 
noninferior for the reduction of HbA1c from baseline237.
A meta-analysis of RCTs of ≥12 weeks duration in 
which information about ethnicity was available showed 
that the WMD in HbA1c for GLP-1RA treatment com-
pared with placebo was −1.16% (95% CI −1.48% to 
−0.85%) in the pool of studies involving ≥50% Asian 
participants, and −0.83% (95% CI −0.97% to −0.70%) in 
the studies with <50% Asian participants (between-group 
difference −0.32%, 95% CI −0.64% to −0.01%, P = 0.04)264.
Effect on weight. GLP-1RAs are associated with reduc-
tions in body weight and waist circumference, but with 
much variation in individual responses and within-class 
differences250,265–268 (see Supplementary information S5 
(table)). In a meta-analysis266 of 15 RCTs, the combi-
nation of GLP-1RAs with basal insulin was shown to 
result in mean weight loss of −3.22 kg (95% CI −4.90 kg 
to −1.54 kg).
Effect on blood pressure. Results from individual RCTs 
and meta-analyses have shown that GLP-1RAs result 
in modest, but significant, reductions in systolic blood 
pressure, compared with placebo or insulin269–271 (see 
Supplementary information S5 (table)). This effect is inde-
pendent of baseline blood pressure and the influence of 
the GLP-1RA on HbA1c or body weight269. A reduction in 
diastolic blood pressure compared with placebo has also 
been observed with exenatide twice daily (−1.08 mmHg, 
95% CI −1.78 mmHg to −0.33 mmHg)270.
Other effects. A meta-analysis has shown that GLP-1RAs 
modestly reduce levels of total cholesterol, LDL choles-
terol and triglycerides, but do not improve HDL cho-
lesterol levels, in comparison with placebo or active 
comparators272.
Safety and adverse effects
GLP-1RAs are generally well tolerated; the most com-
mon adverse effect is nausea, which is usually transient, 
resolving over 4–8 weeks, and which can be minimized 
by progressively increasing the dose27,28,239,250. The risk 
of hypoglycaemia in patients receiving GLP-1RAs is 
low, unless they are combined with insulin or sulfonyl-
ureas27,28,239,250. Injection-site reactions are common 
with some GLP-1RAs, including exenatide once weekly 
(≤17.6%) and albiglutide (≤22%)250. The occurrence of 
antibodies is also commonly associated with GLP-1RA 
treatment, but with little apparent clinical relevance, and 
generally with no influence on glycaemic control, except 
very occasionally in patients receiving exenatide once 
weekly who have high antibody titres28,194,239,250.
The possible association between GLP-1RAs and the 
risk of pancreatitis and pancreatic cancer has received 
much attention, but to date no definite causal link has 
been found273. Meta-analyses have shown no significant 
increase in acute pancreatitis with GLP-1RA treatment 
in patients with T2DM179,274,275. In addition, results from 
cardiovascular safety trials have not shown a significant 
increase in pancreatitis with GLP-1RAs276. The recom-
mendation in the product labelling for GLP-1RAs to 
avoid therapy in patients with a history of pancreatitis 
and to discontinue treatment if pancreatitis develops is 
considered appropriate28. Thyroid C-cell hyperplasia and 
medullary cell carcinoma were also raised as possible 
concerns in preclinical studies in rodents, but clinical 
studies have not identified any substantial problems with 
GLP-1RA treatment28,239,250.
The results of preclinical studies showed that 
GLP-1RAs have cardioprotective effects in heart fail-
ure and following myocardial ischaemia65. GLP-1RAs 
can have favourable effects on many cardiovascular risk 
factors, such as weight loss, blood pressure, endothelial 
function, inflammation, plasminogen activator inhib-
itor-1, postprandial lipaemia and LDL cholesterol65. 
Results of studies in patients with and without T2DM 
have shown a beneficial effect of GLP-1RAs on left 
ventricular function in patients with heart failure and 
on myocardial function and the myocardial salvage 
index following ischaemia65,277. However, GLP-1RAs 
often stimulate the resting heart rate by ~3 bpm, most 
likely by activating GLP-1R in the sinoatrial node65. In 
an RCT271 with 24-h ambulatory heart-rate monitor-
ing, dulaglutide 1.5 mg was associated with increased 
heart rate compared with placebo (LSMD 2.8 bpm, 
95% CI 1.5–4.2 bpm), unlike dulaglutide 0.75 mg and 
exenatide271,278. Large RCTs assessing the cardiovascular 
safety of liraglutide, semaglutide, exenatide once weekly 
and dulaglutide are ongoing65. No adverse cardiovascular 
outcomes have been reported in patients with T2DM and 
established cardiovascular disease who were treated with 
lixisenatide276.
Head-to-head comparisons of GLP-1RAs
As several GLP-1RAs are available, with different chem-
ical structures and formulations, the different phar-
macokinetic and pharmacodynamic profiles seen in 
head-to-head trials could influence clinical decision- 
making205,216,219–221,227,230,231,238,279 (TABLE 2). Overall, liraglu-
tide 1.8 mg and dulaglutide 1.5 mg seem to have the great-
est effects on HbA1c, and liraglutide 1.8 mg and exenatide 
once weekly have the largest effect on weight reduction. 
Albiglutide has less effect on HbA1c and weight reduction 
than other GLP-1RAs, but is associated with fewer gastro-
intestinal adverse effects. Once weekly preparations are 
associated more with injection-site reactions than once 
daily or twice daily agents.
In general, longer-acting GLP-1RAs produce greater 
reductions in FPG, but have less effect on postpran-
dial glucose excursions, compared with shorter-acting 
GLP-1RAs280,281. The effect on postprandial glucose is 
at least partly mediated by delayed gastric emptying, 
and occurs more with short-acting GLP-1RAs than 
with long-acting GLP-1RAs, which are subject to tachy-
phylaxis brought on by chronic elevation of plasma 
GLP-1 (REF. 280). In addition, lixisenatide, in contrast to 
liraglutide, strongly suppresses postprandial glucagon 
secretion280. Patient satisfaction is greater in those receiv-
ing exenatide once weekly or liraglutide, compared with 
exenatide twice daily279.
GLP-1RAs versus insulin
In a meta-analysis282 of RCTs that compared GLP-1RAs 
with basal insulin progressively titrated to achieve FPG 
targets in patients with T2DM, GLP-1RAs resulted in 
greater reductions in HbA1c (mean net change −0.14%, 
95% CI −0.27% to −0.02%, P = 0.03) and weight (−4.40 kg, 
95% CI −5.23 kg to −3.56 kg, P <0.01), but less reduction 
in FPG (1.18 mmol/l, 95% CI 0.43–1.93 mmol/l, P <0.01). 
GLP-1RAs were also associated with greater reduc-
tions in postprandial glucose compared with insulin282. 
Hypoglycaemia was reported to reduce in the GLP-1RA 
group (HR 0.45, 95% CI 0.27–0.76, P <0.01)282. In a 
separate RCT283, dulaglutide resulted in greater reduc-
tion in HbA1c than insulin glargine, when added to 
insulin lispro.
Insulin–GLP-1RA combination
To simplify the co-administration of basal insulin and 
GLP-1RAs, these two agents have been combined into 
a single injection, a fixed-ratio combination (IDegLira), 
which was launched in the UK in 2014 (REF.  147). 
IDegLira combines 50 U of insulin degludec with 1.8 mg 
of liraglutide147; the combination is titrated in the same 
way as insulin alone147.
In a 26-week RCT284 involving insulin-naive patients, 
HbA1c decreased by 1.9% ± 1.1% with IDegLira, com-
pared with 1.4% ± 1.0% with insulin degludec and 
1.3% ± 1.1% with liraglutide. The IDegLira group had 
fewer reports of nausea than the liraglutide group and 
lower incidence of hypoglycaemia than the insulin deglu-
dec group284. These benefits were maintained at 52 weeks, 
with HbA1c reductions of 1.84%, 1.40% and 1.21% for 
IDegLira, insulin degludec and liraglutide, respectively285. 
FPG was similar with IDegLira (5.7 mmol/l) and insu-
lin degludec (6.0 mmol/l) by the end of the study, but 
higher with liraglutide (7.3 mmol/l)285. The improve-
ments in glycaemic control were achieved with 37% 
less daily insulin dose with IDegLira than with insulin 
degludec285. IDegLira was associated with a significantly 
greater decrease in body weight (estimated treatment 
difference −2.80 kg, P <0.0001) and a 37% lower rate 
of hypoglycaemia compared with insulin degludec285. 
In patients who were already receiving basal insulin, 
HbA1c decreased by 1.9% with IDegLira versus 0.9% with 
insulin degludec (treatment difference −1.1%, 95% CI 
−1.3% to −0.8%, P <0.0001). Mean weight reduction 
with IDegLira was 2.7 kg versus no weight change with 
insulin degludec, and the incidence of hypo glycaemia 
was similar (24% for IDegLira versus 25% for insu-
lin degludec)286. Another fixed-ratio combination of 
lixisenatide and insulin glargine has completed phase III 
trials and a regulatory submission has been made 
to the FDA287,288.
SGLT2 inhibitors
SGLT2 inhibitors currently available in Europe and North 
America are dapagliflozin, canagliflozin and empag-
liflozin. They can be used as monotherapy when diet 
and exercise are inadequate, and when metformin is not 
tolerated, and can also be used as add-on to other glu-
cose-lowering agents, including insulin289. As their 
efficacy is dependent on the renal filtration of glucose, 
SGLT2 inhibitors should not be initiated in patients with 
eGFR <60 ml/min/1.73 m2, but in patients who are 
already receiving, and are tolerant of, canagliflozin or 
empagliflozin, these medications can be continued in 
patients with eGFR as low as 45 ml/min/1.73 m2 (REF. 290).
Mechanism of action
SGLTs are secondary active membrane symporters that 
transfer sodium down its concentration gradient, usu-
ally into the cell, in conjunction with the transfer of 
specific hexose sugars or other molecules against their 
concentration gradient291. SGLTs in the intestine and 
kidneys transfer glucose across the luminal membrane 
into enterocytes or ductal epithelial cells; glucose trans-
porters (GLUTs) mediate passive transfer of glucose 
across basolateral membranes down its concentration 
gradient289,292,293.
The main SGLTs are SGLT1 and SGLT2, which are 
primarily responsible for intestinal glucose absorption 
and for reabsorption of most of the filtered glucose in 
the kidney, respectively291,294. SGLT2 is a low-affinity, 
high-capacity glucose transporter in the S1 segment of 
the proximal tubules, which is suited to reabsorption 
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of a high concentration of filtered glucose entering the 
tubules. SGLT1, which is also expressed in the kidneys, 
is a high-affinity, low-capacity glucose transporter that is 
suited to reabsorption of glucose at low concentration in 
the S3 segment of the proximal tubules294–296.
Competitively inhibiting SGLT2 can eliminate 
60–90 g glucose per day297, but this amount can vary con-
siderably depending on renal function and the degree of 
hyper glycaemia289. The effects of SGLT2 inhibition are 
self-limiting, as the efficacy decreases as hyperglycaemia 
lessens (and less glucose is filtered in the kidney). The 
effects of SGLT2 inhibition are insulin-independent, and 
efficacy is not affected by declining β-cell function or 
insulin resistance28,289. However, insulin is still required, 
as SGLT2 inhibition does not treat the underlying 
endocrinopathies that contribute to the pathogenesis 
of T2DM, except by reducing the effects of glucotoxic-
ity28,289. SGLT2 inhibition and the associated glycosuria 
result in mild diuresis and calorie loss, leading to mod-
est reductions in blood pressure and body weight28,289. 
However, the weight loss associated with SGLT2 inhibi-
tors is less than expected from the degree of glycosuria; 
patients typically have one-quarter to one-third of the 
weight loss predicted by their glycosuria. This effect is 
partly accounted for by an elevation of calorie intake, 
which correlates negatively with baseline BMI and pos-
itively with baseline eGFR298. In an RCT299 that included 
95 patients who were taking a GLP-1RA (which should 
counter increased calorie intake), addition of canagli-
flozin 300 mg resulted in significant weight loss com-
pared with placebo (LSMD for change in weight −3.2%, 
95% CI −4.5% to −2.0%) over 18 weeks.
Pharmacokinetics
The currently available SGLT2 inhibitors have half-lives 
of 10.6 h to 13.3 h289,300–304 (see Supplementary infor-
mation S7 (box)). Empagliflozin is the most specific. 
SGLT2 inhibition by dapagliflozin (10 mg per day), can-
agliflozin (300 mg per day) or empagliflozin (25 mg per 
day) increases urinary glucose excretion by 60–90 g per 
day289,302,303. SGLT2 inhibitors are metabolized by uridine 
diphosphate glucuronosyl transferases, and no significant 
interactions with other drugs have been reported289,305,306.
Pharmacodynamics
Dapagliflozin. In a 24-week RCT307 involving drug-naive 
patients with T2DM, compared with placebo, dapagli-
flozin 5–10 mg per day reduced HbA1c by 0.8–0.9%, and 
reduced body weight by 2.8–3.2 kg. A meta-analysis308 
of RCTs of 12–104 weeks duration showed that dapagli-
flozin (2.5–10.0 mg per day) improved HbA1c, FPG and 
weight compared with placebo when used as an add-on 
therapy to metformin, insulin, thiazolidinediones, sul-
fonylureas or metformin ± sitagliptin (mean difference 
between groups −0.52%, 95% CI −0.60% to −0.45%, 
−1.52 mmol/l, 95% CI −1.75 mmol/l to −1.29 mmol/l and 
−1.61 kg, 95% CI −1.97 kg to −1.26 kg, respectively). The 
reductions in HbA1c and FPG compared with placebo 
were generally similar with different background treat-
ments, but were greatest when dapagliflozin was added 
to a sulfonylurea (−0.96%, 95% CI −0.86% to −0.52% and 
−1.47 mmol/l, 95% CI −1.86 mmol/l to −1.08 mmol/l)308. 
The largest between-group difference in weight change 
was seen when dapagliflozin was added to insulin 
(−2.45 kg, 95% CI −2.99 kg to −1.92 kg)308.
Dapagliflozin and glipizide were compared in a 
52-week RCT with a 156-week extension309; dapagliflozin 
resulted in lesser HbA1c reductions in the initial 18-week 
titration phase, but the 18–104-week coefficient of fail-
ure was lower with dapagliflozin (0.13% per year) than 
with glipizide (0.59% per year). HbA1c reductions were 
greater with dapagliflozin by week 104 (difference from 
glipizide −0.18%, 95% CI −0.33% to −0.03%, P = 0.021)309. 
Dapagliflozin also resulted in sustained reductions in 
weight and systolic blood pressure (104-week differences 
from glipizide −5.1 kg, 95% CI −5.7 kg to −4.4 kg and 
−3.9 mmHg, 95% CI −6.1 mmHg to −1.7 mmHg, respec-
tively)309. In an RCT310 involving 180 patients with T2DM 
inadequately controlled by metformin, a modest level of 
weight loss with dapagliflozin add-on compared with 
placebo was associated with significant improvements in 
health-related quality of life over 102 weeks. In an RCT311 
involving 18 men with T2DM, in comparison with pla-
cebo dapagliflozin resulted in increased glucagon secre-
tion from as early as 1 h after administration, reaching a 
peak after 4 h. After 3 days of dapagliflozin treatment, the 
fasting plasma glucagon concentration was 32% higher 
than on day 1, compared with no change in the placebo 
group311. The increase in glucagon was associated with 
increased endogenous glucose production311. The mech-
anism underlying this apparently compensatory change is 
not known, although SGLT2 expression has been noted in 
pancreatic α cells312.
Canagliflozin. In a meta-analysis of RCTs, canagliflozin 
was found to reduce HbA1c when used as monotherapy 
(WMD −1.08%, 95% CI −1.25% to −0.90%, P <0.00001) 
or add-on treatment (−0.73%, 95% CI −0.84% to −0.61%, 
P <0.00001), compared with placebo313. Relative to active 
comparators, canagliflozin reduced HbA1c by −0.21% 
(95% CI −0.33% to −0.08%, P = 0.001)313. Canagliflozin 
also reduced HbA1c in comparison with sitagliptin 
(−0.24%, 95% CI −0.40% to −0.09%, P = 0.002) and 
glimepiride (−0.12%, 0.95% CI −0.23% to −0.01%, 
P = 0.03)313, and reduced FPG in comparison with placebo 
(−33.50 mg/dl, 95% CI −39.22 mg/dl to −27.78 mg/dl, 
P <0.00001) and active comparators (−15.86 mg/dl, 
95% CI −23.17 mg/dl to −8.56 mg/dl, P <0.00001)313. 
Canagliflozin resulted in greater weight loss than pla-
cebo (−2.81 kg, 95% CI −3.26 kg to −2.37 kg) or active 
comparators (−3.49 kg, 95% CI −4.86 kg to −2.12 kg), 
particularly when compared with glimepiride (−5.40 kg, 
95% CI −5.95 kg to −4.85 kg, P <0.00001)313.
Addition of canagliflozin to insulin treatment (gen-
erally by a basal–bolus regimen) has been shown to 
result in a significant reduction in HbA1c at 18 weeks 
(and sustained up to 52 weeks) compared with placebo, 
from a baseline of 8.3% (−0.62%, 95% CI −0.69% to 
−0.54%, P <0.001 with 100 mg canagliflozin and −0.73%, 
95% CI −0.81% to −0.65%, P <0.001 with 300 mg can-
agliflozin)314. In an RCT involving 37 patients, follow-
ing an initial dose of canagliflozin, a second dose of 
300 mg canagliflozin administered immediately before 
a mixed-meal tolerance test reduced postprandial glu-
cose (compared with placebo) without causing further 
increases in urinary glucose excretion, which suggests 
the induction of mechanisms such as SGLT1 inhibition 
in the gut315. Glucose lowering and weight loss with can-
agliflozin are more durable than with sulfonylureas at 
104 weeks316.
Reductions in systolic and diastolic blood pressure 
have been demonstrated for canagliflozin compared with 
placebo (systolic −5.05 mmHg, 95% CI −6.81 mmHg to 
−3.28 mmHg, P <0.00001, diastolic −2.43 mmHg, 95% CI 
−3.29 mmHg to −1.57 mmHg, P <0.0001) or active com-
parators (systolic −4.34 mmHg, 95% CI −5.31 mmHg 
to −3.36 mmHg, P <0.00001, diastolic −2.17 mmHg, 
95% CI −2.79 mmHg to −1.54 mmHg, P <0.00001)313.
Empagliflozin. In 24-week RCTs317–320, empagliflozin 
(as monotherapy or added to metformin, to met-
formin with sulfonylurea or to pioglitazone with or 
without metformin) resulted in reductions in HbA1c, 
body weight and systolic blood pressure of 0.7–0.8%, 
1.5–2.5 kg and 2.9–4.1 mmHg respectively, which were 
significant in comparison with placebo. Reductions in 
HbA1c and weight were maintained in trial extensions 
up to 76 weeks321–324.
Compared with sitagliptin monotherapy for 
24 weeks, empagliflozin monotherapy resulted in similar 
HbA1c reductions, but greater reductions in FPG, body 
weight and systolic blood pressure317. Over 104 weeks, 
empagliflozin was noninferior to glimepiride as an 
add-on to metformin treatment, and resulted in less 
hypoglycaemia325.
In patients receiving basal insulin (with or without 
the additional regimen of metformin with or without 
sulfonylurea), empagliflozin resulted in HbA1c reduc-
tion of 2.0–2.5% compared with placebo over 78 weeks, 
along with 2.4–4.1 kg weight loss326. Addition of pla-
cebo, empagliflozin 10 mg or empagliflozin 25 mg to a 
multiple daily injection insulin regimen reduced HbA1c 
(−0.81 ± 0.08%, −1.18 ± 0.08% and −1.27 ± 0.08%, respec-
tively) after 52 weeks327. Insulin dose and body weight 
were reduced (by −9 to −11 international units per day 
and −2.4 kg to −2.5 kg, respectively) with empagliflozin 
treatment compared with placebo, without increasing 
the risk of hypoglycaemia327.
In a 12-week RCT328 of patients with T2DM, base-
line systolic blood pressure of 130–159 mmHg and 
diastolic blood pressure of 80–99 mmHg, the adjusted 
mean difference versus placebo in change from baseline 
in mean 24-h systolic blood pressure was −4.16 mmHg 
(95% CI −5.50 mmHg to −2.83 mmHg), and in diastolic 
blood pressure was −1.72 mmHg (95% CI −2.51 mmHg 
to−0.93  mmHg) with 25 mg empagliflozin (both 
P <0.001).
Compared with placebo, empagliflozin resulted in 
an adjusted mean HbA1c difference of −0.68% (95% CI 
−0.88% to −0.49%) in patients with eGFR 60–90 ml/
min/1.73 m2 and −0.42% (95% CI −0.56% to −0.28%) in 
patients with eGFR 30–60 ml/min/1.73 m2 over 24 weeks, 
and the treatment was well tolerated329.
Safety and adverse effects
SGLT2 inhibitors are associated with low risk of hypo-
glycaemia except when used in combination with insu-
lin or sulfonylureas289. This low risk reflects the ability 
of uninhibited SGLT2 (and SGLT1) to reabsorb all of 
a reduced filtered glucose load as the blood glucose 
level declines, emphasizing the self-limiting nature of 
this mode of action289. Compared with the sulfonylurea 
glipizide, dapagliflozin resulted in significantly lower 
risk of hypoglycaemia (4.2% versus 45.8%) in an RCT 
involving 814 patients with T2DM over 104 weeks309. 
Canagliflozin treatment was associated with similar rates 
of hypoglycaemia to placebo when used as monotherapy 
or as an add-on therapy, except when added to sulfo-
nylurea (RR 1.49, 95% CI 1.14–1.95, P = 0.004)313. The 
percentage of patients having confirmed hypoglycaemic 
events with empagliflozin treatment has been shown to 
be <1% when used as monotherapy, 1.4–2.4% when used 
as add-on to metformin or pioglitazone, 11.5–16.1% 
when combined with sulfonylureas and 35–58% when 
added to insulin28,239,305.
SGLT2 inhibitors are associated with increased risk of 
genital infections, but an increase in urinary tract infection 
(UTI) has not been consistently reported289. Compared 
with sulfonylureas, dapagliflozin has been associated with 
increased risk of genital and urinary tract infections 
(14.8% and 13.5%, respectively, with dapagliflozin, 2.9% 
and 9.1%, respectively, with glipizide)309. No increased 
risk of UTIs was observed in patients treated with can-
agliflozin, but the risk of genital tract infections was 
increased (RR 3.76, 95% CI 2.23–6.35, P <0.00001 versus 
placebo, RR  4.95, 95%  CI 3.25–7.52, P <0.00001 
versus active comparators); the increase was greater in 
women than in men, but none of the reported infections 
was severe and all were resolved with simple treatment313. 
In a pooled analysis of RCTs330, genital mycotic infection 
occurred more commonly with canagliflozin 100 mg and 
300 mg than with placebo in women (10.4%, 11.4% and 
3.2%, respectively) and in men (4.2%, 3.7% and 0.6%, 
respectively). Similar results were found when canagli-
flozin was compared with active control (14.7%, 13.9% 
and 3.1% in women, 7.3%, 9.3% and 1.6% in men)330. 
The infections were generally mild and easy to treat, but 
laboratory confirmation was lacking for most events330. 
Similarly, a review of the properties of empagliflozin 
found an association with UTI in some trials, but not 
others, whereas all trials showed increased risk of genital 
infections305.
SGLT2 inhibitors are associated with small increases 
in LDL cholesterol, but also corresponding increases in 
HDL cholesterol; these effects might be slightly greater 
with canagliflozin than with other SGLT2 inhibitors313,331. 
Results differ with regard to the risk of osmotic diuresis 
and hypovolaemia289,332. In a meta-analysis313, the risks of 
adverse effects related to osmotic diuresis were found to 
be higher with canagliflozin than with placebo (RR 3.93, 
95% CI 2.25–6.86, P <0.00001) or active comparators 
(RR 2.57, 95% CI 1.26–5.25, P = 0.009), whereas vol-
ume-related adverse effects did not differ. In a 12-week 
RCT333, canagliflozin 300 mg resulted in decreased plasma 
volume at week 1 (−5.4% versus 4.3% with placebo, 
P = 0.02), along with a modest increase in urinary volume, 
both of which were attenuated by week 12. In a pooled 
analysis334 of data from >11,000 patients with T2DM, 
empagliflozin was not associated with the frequency of 
events related to volume depletion, but a high frequency 
of such events occurred in patients ≥75 years of age receiv-
ing empagliflozin 25 mg, and in patients receiving loop 
diuretics in addition to empagliflozin 10 mg.
SGLT2 inhibitors, particularly canagliflozin, might 
have adverse effects on the risk of fractures. The results 
of an RCT335 with dapagliflozin showed no effect on 
markers of bone formation or resorption, or bone min-
eral density after 50 weeks of treatment in men and post-
menopausal women with T2DM inadequately controlled 
by metformin334,335. However, in some studies, canagli-
flozin has been shown to affect levels of urinary calcium, 
serum phosphate and 1,25-dihydroxyvitamin D336. In a 
26-week RCT336 with a 78-week extension that included 
716 patients with T2DM aged 55–80 years, canagliflozin 
treatment was associated with a decrease in total hip 
bone mineral density over 104 weeks (placebo-subtracted 
changes −0.9% and −1.2% for 100 mg and 300 mg canag-
liflozin, respectively), but no effect was seen at other bone 
sites. In a pooled analysis of eight studies (n = 5,867), the 
incidence of fractures was similar with (1.7%) and with-
out (1.5%) canagliflozin (HR 1.09, 95% CI 0.71–1.66)337. 
Separate analysis of results from the CANVAS trial 
(n = 4,327) showed a significant increase in fractures 
with canagliflozin (4.0%) compared with placebo (2.6%; 
HR 1.51, 95% CI 1.04–2.19), as well as increased fall- 
related adverse effects337. However, compared with the 
non-CANVAS trials, patients in the CANVAS trial were 
older (62.4 ± 8.0 years versus 57.6 ± 9.8 years), with a high 
risk of cardiovascular disease, and with lower baseline 
eGFR and higher diuretic use337.
Several instances of euglycaemic and hyperglycaemic 
diabetic ketoacidosis have been reported in patients who 
received SGLT2 inhibitors338–341. The diabetic ketoacidosis 
prevalence in 17,596 patients from randomized studies of 
canagliflozin was 0.07% (n = 12)341. Many of the affected 
patients, with T2DM treated with insulin, had reduced 
or stopped insulin or experienced an intercurrent illness 
that would increase the demand for glucose342. A lack 
of insulin leads to increased lipolysis and conversion of 
excess fatty acids to ketones, but the hyperglycaemia asso-
ciated with SGLT2 inhibitors is typically mild, presum-
ably because they reduce blood glucose338,339,342. In many 
of the occurrences of diabetic ketoacidosis, reduction 
of insulin dose revealed latent autoimmune diabetes of 
adults, a form of type 1 diabetes mellitus (T1DM). Other 
instances of diabetic ketoacidosis resulted from off-label 
use of SGLT2 inhibitors in patients with T1DM338,339,342. 
Patients treated with insulin and undertaking self- 
monitoring of blood glucose should not, therefore, dis-
continue insulin when they observe a reduction in blood 
glucose after introduction of an SGLT2 inhibitor. The 
SGLT2 therapy can improve glycaemic control, but does 
not obviate the need for insulin.
Pooled analysis of the results of phase II and phase III 
trials suggests a beneficial effect of dapagliflozin on cardi-
ovascular disease65. Cardiovascular outcomes in patients 
treated with SGLT2 inhibitors are being assessed in a 
number of RCTs. In a study of 7,020 patients with T2DM 
at high risk of cardiovascular events, occurrence of a 
composite end point of nonfatal myocardial infarction, 
nonfatal stroke and death from cardiovascular causes 
was lower with empagliflozin than placebo, in addi-
tion to standard therapy (HR 0.86, 95% CI, 0.74–0.99, 
P = 0.04 for superiority)343. Empagliflozin treatment 
also reduced the risk of cardiovascular death (HR 0.62, 
95% CI, 0.49–0.77, P <0.001), death from any cause 
(HR 0.68, 95% CI, 0.57–0.82, P <0.001) and hospitali-
zation from heart failure (HR 0.65, 95% CI, 0.50–0.85, 
P = 0.002)343. Subgroup analyses showed heterogeneity 
for the primary outcome; the benefits of empagliflozin 
were more evident in the Asian population, in patients 
with BMI <30 kg/m2 and HbA1c <8.5%, in those not on 
insulin treatment and in those with nephropathy343. The 
effect of empagliflozin on death from cardiovascular 
causes was consistent across all subgroups343. Results of 
other cardiovascular outcome trials with dapagliflozin 
and canagliflozin are awaited with interest.
Other agents
Dopamine D2 receptor agonists
Bromocriptine quick release (QR) is a dopamine D2 
receptor agonist that is licensed in some countries 
outside Europe for treatment of T2DM as an adjunct 
to lifestyle changes344,345. The effect of bromocriptine 
on glycaemic parameters has been noted since 1980 
(REF. 346). The drug provides a morning boost to hypo-
thalamic dopamine levels, consistent with normal diur-
nal glucoregulation, and contributing to a reduction of 
sympathetic tone, neural suppression of hepatic glucose 
production and improvement in peripheral glucose 
disposal, without affecting insulin levels28,344,346,347. A 
meta-analysis showed that bromocriptine QR add-on 
therapy, compared with placebo, reduced levels of 
HbA1c (−6.52 mmol/mol, 95% CI −8.07 mmol/mol 
to −4.97 mmol/mol) and FPG (−1.04 mmol/l, 95% CI 
−1.49 mmol/l to −0.59 mmol/l), but had no effect on 
postprandial glucose348. Bromocriptine QR was weight 
neutral and was not associated with the risk of hypo-
glycaemia, hypotension or cardiovascular effects348. 
However, bromocriptine QR increased gastrointesti-
nal adverse effects of nausea and vomiting, relative to 
placebo348. In an RCT349 involving 3,095 patients, bro-
mocriptine QR (as monotherapy or add-on to glucose- 
lowering agents, including insulin) was shown to reduce 
the risk of cardiovascular disease, compared with placebo 
(HR 0.60, 95% CI 0.35–0.96) by 52 weeks.
Bile-acid sequestrants
Bile-acid sequestrants are established treatments for 
dyslipidaemia and are associated with a reduction in 
the risk of cardiovascular disease350. In 2008, the FDA 
licensed colesevelam as an adjunct to lifestyle measures 
to improve glycaemic control in T2DM26. The mecha-
nism of action might involve the passage of bile acids 
along the intestine, possibly activating bile-acid recep-
tors on L cells, leading to secretion of GLP-1. Inhibiting 
the return of bile acids to the liver could also affect 
glucose metabolism by preventing activation of hepatic 
farnesoid receptors28. Colesevelam reduced HbA1c by 
0.30–0.54% compared with placebo, in combination 
with metformin, sulfonylureas, pioglitazone or insu-
lin, with no increased risk of hypoglycaemia or weight 
gain350,351. Despite its favourable effect on levels of LDL 
cholesterol and HDL cholesterol, colesevelam increased 
levels of triglycerides by 11–22%350.
Pramlintide
Pramlintide, a soluble analogue of islet amyloid poly-
peptide, was introduced in 2005 as an injectable meal-
time adjunct to a basal–bolus insulin regimen352. It 
assists glycaemic control and weight control through a 
centrally-mediated effect via the area postrema, which 
activates neural pathways that enhance satiety, suppress 
pancreatic glucagon secretion and slow gastric empty-
ing352. Modest reductions in HbA1c, typically 0.3–0.6%, 
have been reported alongside body-weight reductions 
of 1–2 kg and reductions of the bolus insulin require-
ment352. Addition of pramlintide to treatment adds to 
the burden of mealtime injections and requires care 
with dose adjustments to minimize risks of nausea and 
hypoglycaemia352.
Treatment algorithm
The treatment options for patients with T2DM now 
extend to a variety of drug classes with different mecha-
nisms of action, low risks of hypoglycaemia and favour-
able effects on body weight. The availability of several 
agents within most classes offers choice with regard to 
pharmacokinetics, pharmacodynamics and the timing 
and mode of delivery. However, direct comparisons can 
be difficult when long-term head-to-head studies are not 
available, as can determining suitability for individual 
patients in the absence of studies in particular patient 
subgroups. Overall, the choice of treatment must bal-
ance efficacy with safety, tolerability with adherence and 
budgets with resources, as well as considering practical 
issues relating to realistic targets, monitoring and life 
situations36.
Metformin is firmly established as the preferred 
first-line pharmacotherapy in patients with T2DM36. 
Expectations are increasing for SGLT2 inhibitors, and 
the results of ongoing RCTs will help to determine the 
positioning of this class in the treatment algorithm. 
Notably, the choice of metformin as first-line therapy 
is mainly based on the results of the UKPDS, which 
included 342 patients assigned to metformin, whereas 
the efficacy of empagliflozin has been demonstrated in 
4,687 patients in the EMPA–REG study343. The EMPA–
REG study included patients with advanced disease and 
high risk of cardiovascular disease, whereas the UKPDS 
population had newly diagnosed T2DM. If HbA1c targets 
are not met with metformin treatment within 3 months, 
the recommendation from the American Diabetes 
Association and the European Association for the 
Study of Diabetes is to add a differently-acting agent36. 
Although oral agents will often have similar efficacy, the 
injectables (GLP-1RAs and insulin) can have greater 
effects on HbA1c241. However, efficacy is not just about 
HbA1c, but must always take into account a ‘package’ of 
effects that includes risk of hypoglycaemia, weight gain, 
general tolerability and long-term safety. For example, 
the risks of weight gain and hypoglycaemia are higher 
with sulfonylureas and insulin than with DPP-4 inhibi-
tors and SGLT2 inhibitors36. Thiazolidinediones have a 
low risk of hypoglycaemia, but increase body weight and 
the risks of heart failure and bone fractures, compared 
with placebo36. An individualised approach to treatment 
is important, taking into account patients’ circumstances 
and needs. Therapeutic choice is restricted in people 
who drive, the elderly, the frail and those with renal, 
neural and other comorbidities.
If the addition of a second agent fails to achieve or 
maintain acceptable glycaemic control, adding a third 
differently acting agent can be indicated36. Most classes of 
agents can be combined with additive efficacy, although 
addition of DPP-4 inhibitors to GLP-1RAs is unlikely 
to offer extra control. If triple combinations are inad-
equate, introduction of insulin (usually basal initially 
with continued metformin) is needed. If basal insulin is 
insufficient, addition of meal-time insulin, a GLP-1RA 
or possibly an SGLT2 inhibitor can be considered36. 
Addition of a GLP-1RA in this context might be a useful 
treatment strategy, as it has less risk of hypoglycaemia 
than meal-time insulin, and has a better effect on weight.
The availability of increasing numbers of agents that 
are given at a frequency less than daily might be attrac-
tive for many patients, and might enhance compliance. 
The outcomes of ongoing cardiovascular safety studies 
could further clarify the T2DM treatment algorithm, 
as could the introduction of additional long-acting 
GLP-1RAs, DPP-4 inhibitors and SGLT2 inhibitors that 
are in development18,26,353–357.
Lessons for future therapies
Advances in the understanding of the pathogenesis 
of T2DM have informed the development of different 
classes of treatments358. However, treatments are needed 
with longer lasting metabolic effects than those currently 
available, and with the ability to improve, or prevent con-
tinuing decline in, β-cell function. Clearly, safety is of 
paramount importance. Adverse effects have been found 
with several agents that have now been discontinued, 
highlighting the importance of maintaining pharma-
covigilance. Minimizing hypoglycaemia, weight gain 
and cardiovascular events while avoiding any increased 
risk of cancer is crucial for new treatments, particularly 
as they might need to be taken for many years. In real 
life, medications will be used in more varied populations 
than in clinical trials, and they might be prescribed by 
less-specialized professionals to patients who will not 
receive the intensive follow-up and monitoring associated 
with RCTs359.
When considering safety, it can be extremely diffi-
cult to interpret results from preclinical studies, or to 
have available the most appropriate models to decide 
which treatments should be developed further. Another 
challenge is to identify and interpret adverse signals in 
clinical trials for extrapolation to real life359. Faint sig-
nals from preregistration trials can take a decade or 
more to reveal their clinical importance and are often 
confounded by several biases, including treatment 
allocation and detection of complications. Pressure to 
ensure safety is increasing, but regulatory agencies have 
a difficult task to strike a balance between appropri-
ate caution and making sure that new beneficial treat-
ments are made available in a safe, but timely manner359. 
Understanding the factors responsible for variations in 
the responses of individuals to particular treatments, 
and the influence of pharmacogenetics on pharma-
cokinetics and efficacy will facilitate personalized and 
patient-centred therapies29.
Conclusion
Many different glucose-lowering therapies are now 
available to address different aspects of the pathogenesis 
of T2DM through a range of actions, and these treat-
ments vary in efficacy, convenience, adverse effect pro-
files and cost. The potential ‘value’ of a therapy involves 
more than a cost–benefit analysis, and is based on a 
‘package’ of attributes that takes account of long-term 
safety, tolerability, risk of hypoglycaemia and weight 
gain and suitability in the presence of comorbidities 
and other medications. Individualized therapy must be 
tailored to patients’ needs and preferences, with con-
sideration of their circumstances, understanding and 
commitment.
DPP-4 inhibitors, GLP-1RAs and SGLT2 inhibitors 
have low risks of hypoglycaemia (except when combined 
with insulin or sulfonylurea) and are associated with 
either weight loss or weight neutrality, but they are more 
expensive than older agents such as sulfonylureas and 
meglitinides. Evidence relating to the safety profiles of 
many of these newer agents is encouraging and suggests 
their value in the challenge to provide early, effective and 
sustained glycaemic control in T2DM. Although met-
formin remains the preferred initial pharmacotherapy 
(when tolerated), an individualized approach is required 
to assess treatment targets and to achieve them in the 
safest possible manner.
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